Edyta Tulewicz-Marti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Edyta Tulewicz-Marti has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Grażyna Rydzewska
Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Woloska 137 St., 02-507 Warsaw, Poland
7 shared publications - Konrad Lewandowski
Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
7 shared publications Grażyna Rydzewska
Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland
3 shared publications- Aleksandra Pechcińska
Department of Oncology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland, Poland
2 shared publications - Hanna Szweda
Department of Obstetrics and Gynaecology, Institute of Mother and Child in Warsaw, 01-211 Warsaw, Poland
2 shared publications - Izabela Sierakowska
Department of Gastroenterology and Internal Medicine, National Medical Institute of the Ministry of the Interior and Administration, Woloska 137 St., 02-507 Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8324
Cervical Cytological Abnormalities in Women with Inflammatory Bowel Disease (IBD) and Non-IBD Controls: A Retrospective Study
Background: Data on cervical cytological abnormalities in women with inflammatory bowel disease (IBD) are inconsistent. We compared their prevalence in women with and without IBD. Methods: In this retrospective single-centre analysis of electronic medical records (2022–2024), women with Crohn’s disease (CD) or ulcerative colitis (UC) were compared with 141 women treated at a gynaecology outpatient clinic. Cytology was classified exclusively using the Bethesda System (abnormal = ASC-US or worse; “Pap II” inflammation = normal). Results: Of 301 women with IBD, 280 (141 CD, 139 UC) had evaluable cytology. The most recent cytology assessment was abnormal in 4/280 women with IBD (1.4%) versus 13/141 controls (9.2%; OR 0.14, 95% CI 0.05–0.45); a current or historical abnormality was identified in 12/280 women with IBD (4.3%) versus 13/141 controls (9.2%; OR 0.44, 95% CI 0.20–0.99; p = 0.051). CD and UC did not differ, and no clinical or treatment variable was associated with abnormality (12 events). hrHPV testing was documented in 15.7% of women with IBD (controls 85.8%). Conclusions: Abnormal cytology was infrequent in this closely monitored IBD cohort and numerically lower than in controls; however, the controls comprised a selected group, HPV testing differed between groups, and events were few, so an increased risk cannot be excluded. Regular gynaecological surveillance remains essential.
- 26 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8324
Open AccessCervical Cytological Abnormalities in Women with Inflammatory Bowel Disease (IBD) and Non-IBD Controls: A Retrospective Study
Background: Data on cervical cytological abnormalities in women with inflammatory bowel disease (IBD) are inconsistent. We compared their prevalence in women with and without IBD. Methods: In this retrospective single-centre analysis of electronic medical records (2022–2024), women with Crohn’s disease (CD) or ulcerative colitis (UC) were compared with 141 women treated at a gynaecology outpatient clinic. Cytology was classified exclusively using the Bethesda System (abnormal = ASC-US or worse; “Pap II” inflammation = normal). Results: Of 301 women with IBD, 280 (141 CD, 139 UC) had evaluable cytology. The most recent cytology assessment was abnormal in 4/280 women with IBD (1.4%) versus 13/141 controls (9.2%; OR 0.14, 95% CI 0.05–0.45); a current or historical abnormality was identified in 12/280 women with IBD (4.3%) versus 13/141 controls (9.2%; OR 0.44, 95% CI 0.20–0.99; p = 0.051). CD and UC did not differ, and no clinical or treatment variable was associated with abnormality (12 events). hrHPV testing was documented in 15.7% of women with IBD (controls 85.8%). Conclusions: Abnormal cytology was infrequent in this closely monitored IBD cohort and numerically lower than in controls; however, the controls comprised a selected group, HPV testing differed between groups, and events were few, so an increased risk cannot be excluded. Regular gynaecological surveillance remains essential.
- Open Access
- 27 February 2026
- Published by MDPI AG in Preprints.org
Women with Inflammatory Bowel Disease Are Not at Risk of Abnormal Cervical Cytology: Results of a Retrospective Study
Introduction: Existing data on cervical intraepithelial neoplasia (CIN) in individuals with inflammatory bowel disease (IBD) are inconsistent. The aim of this study was to evaluate the prevalence of abnormal cervical cytology among patients with IBD. Methods: A retrospective analysis was conducted using digital records from patients with IBD, including those receiving immunosuppressive therapy, small molecules, or biological treatments, to assess the influence of these therapies on cervical cytology results. Results: Data were collected from 301 patients with IBD (150 with Crohn’s disease [50.3%] and 151 with ulcerative colitis [49.8%]) and 40 control patients. The mean age in the IBD group was 36.96 ± 11.92 years for Crohn’s disease and 43.19 ± 14.42 years for ulcerative colitis (mean difference = -6.23, 95% CI [-9.23; -3.23]), while the control group had a mean age of 36.55 ± 12.70 years. Deviations from normal findings in the most recent cytology were observed in 6 IBD patients (2.3%) compared to 8 control patients (20.0%), OR = 0.10, 95% CI [0.03; 0.34], p < 0.001. Deviations from normal findings in the most recent cytology or an y previous cytology were identified in 25 IBD patients (9.0%) versus 9 controls patients (22.5%), OR = 0.34, 95 % CI [0.14; 0.91], p = 0.021. No significant differences were found between the IBD subgroups regarding smoking status, current or past exposure to immunosuppressive drugs, or frequency of gynaecological examinations. The frequency of biological treatment was higher in Crohn’s disease patients (88.0%) compared to those with ulcerative colitis (74.2%) (OR = 2.55, 95% CI [1.36; 5.01], p = 0.003). Conclusions: Women with IBD exhibited a lower risk of cervical dysplasia compared to healthy controls, independent of treatment type. However, rigorous malignancy surveillance, including regular cervical cytology, remains essential to facilitate early detection of dysplasia.
- 27 February 2026
- Published by MDPI AG in Preprints.org
Open AccessWomen with Inflammatory Bowel Disease Are Not at Risk of Abnormal Cervical Cytology: Results of a Retrospective Study
Introduction: Existing data on cervical intraepithelial neoplasia (CIN) in individuals with inflammatory bowel disease (IBD) are inconsistent. The aim of this study was to evaluate the prevalence of abnormal cervical cytology among patients with IBD. Methods: A retrospective analysis was conducted using digital records from patients with IBD, including those receiving immunosuppressive therapy, small molecules, or biological treatments, to assess the influence of these therapies on cervical cytology results. Results: Data were collected from 301 patients with IBD (150 with Crohn’s disease [50.3%] and 151 with ulcerative colitis [49.8%]) and 40 control patients. The mean age in the IBD group was 36.96 ± 11.92 years for Crohn’s disease and 43.19 ± 14.42 years for ulcerative colitis (mean difference = -6.23, 95% CI [-9.23; -3.23]), while the control group had a mean age of 36.55 ± 12.70 years. Deviations from normal findings in the most recent cytology were observed in 6 IBD patients (2.3%) compared to 8 control patients (20.0%), OR = 0.10, 95% CI [0.03; 0.34], p < 0.001. Deviations from normal findings in the most recent cytology or an y previous cytology were identified in 25 IBD patients (9.0%) versus 9 controls patients (22.5%), OR = 0.34, 95 % CI [0.14; 0.91], p = 0.021. No significant differences were found between the IBD subgroups regarding smoking status, current or past exposure to immunosuppressive drugs, or frequency of gynaecological examinations. The frequency of biological treatment was higher in Crohn’s disease patients (88.0%) compared to those with ulcerative colitis (74.2%) (OR = 2.55, 95% CI [1.36; 5.01], p = 0.003). Conclusions: Women with IBD exhibited a lower risk of cervical dysplasia compared to healthy controls, independent of treatment type. However, rigorous malignancy surveillance, including regular cervical cytology, remains essential to facilitate early detection of dysplasia.
- Open Access
- 24 September 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
Multiple effects of microplastic particles on human internal organs – narrative review
Introduction and objective: Microplastics are tiny plastic particles less than 5 millimeters in diameter. Their omnipresence in the environment has raised significant concerns about their potential impacts on human health. The aim of the review is to examine the current state of knowledge...
- 24 September 2025
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
Open AccessMultiple effects of microplastic particles on human internal organs – narrative review
Introduction and objective: Microplastics are tiny plastic particles less than 5 millimeters in diameter. Their omnipresence in the environment has raised significant concerns about their potential impacts on human health. The aim of the review is to examine the current state of knowledge...
- 1 January 2025
- Published by Borgis Sp. z o.o. in Nowa Medycyna
- Vol. 32 (1) , 18-22
Guidelines for oncological surveillance of gastrointestinal changes in patients with inflammatory bowel disease
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a lifelong, chronic condition that remains incurable with current medical knowledge and requires long-term management. Over the course of the disease, precancerous changes may arise. Certain treatment methods may also contribute to their development. This article explores key aspects of oncological surveillance in patients with IBD, presenting current guidelines for monitoring and management based on the latest literature.
- 1 January 2025
- Published by Borgis Sp. z o.o. in Nowa Medycyna
- Vol. 32 (1) , 18-22
Guidelines for oncological surveillance of gastrointestinal changes in patients with inflammatory bowel disease
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is a lifelong, chronic condition that remains incurable with current medical knowledge and requires long-term management. Over the course of the disease, precancerous changes may arise. Certain treatment methods may also contribute to their development. This article explores key aspects of oncological surveillance in patients with IBD, presenting current guidelines for monitoring and management based on the latest literature.
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 20 (3) , 330-334
Efficacy and safety of faecal microbiota transplantation (FMT) in recurrent Clostridioides difficile infection: results of a single-centre retrospective study
Introduction Studies have indicated the high effectiveness of faecal microbiota transplantation (FMT) in the treatment of recurrent Clostridioides difficile infection (rCDI). However, there is still a lack of data from different subpopulations regarding FMT and the factors related to it. Aim...
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 20 (3) , 330-334
Open AccessEfficacy and safety of faecal microbiota transplantation (FMT) in recurrent Clostridioides difficile infection: results of a single-centre retrospective study
Introduction Studies have indicated the high effectiveness of faecal microbiota transplantation (FMT) in the treatment of recurrent Clostridioides difficile infection (rCDI). However, there is still a lack of data from different subpopulations regarding FMT and the factors related to it. Aim...
- Open Access
- 2 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5213
Should the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center
Background: Oncological anxiety associated with biological therapy is a particular challenge in inflammatory bowel disease (IBD), and it has raised questions about the need for the dermatological assessment of the skin before starting biological therapy. Methods: The aim of this study was to assess the frequency of dermal lesions, including cutaneous malignancies, in IBD patients. This retrospective, single-center study evaluated 805 IBD patients who qualified for biological treatment and were subjected to a dermatological assessment. Results: Dermal lesions (DLs) were found in 15.5% (125) of IBD patients. A risk factor for DLs was higher with body mass index (OR = 1.08, 95% CI [1.02; 1.14], p = 0.007). Surprisingly, there was no effect of thiopurines between the groups with and without DLs (90.4% vs. 84.6%, MD = 0.06, 95% CI [0.01; 0.12], p = 0.118). Moreover, cutaneous malignancies were diagnosed in 9 cases (1.1%), including 4 basal cell carcinomas, 4 squamous cell carcinomas, and 1 melanoma skin cancer. Only 13.4% of patients complied with our strict policy of skin surveillance every 6–8 months. Conclusions: DLs, including cutaneous malignancies, are common in patients with IBD, making skin monitoring at the initiation of biological treatment an extremely useful tool. The lack of effect of the drugs used suggests that skin surveillance is necessary in all IBD patients. The low compliance of skin monitoring among immunosuppressed patients indicates the need for better education on the prevention of cutaneous malignancies.
- 2 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5213
Open AccessShould the Dermatological Assessment of Patients with Inflammatory Bowel Disease Become Standard during Qualifications for Biological Treatment? A Retrospective, Single-Center Experience from a Tertiary Center
Background: Oncological anxiety associated with biological therapy is a particular challenge in inflammatory bowel disease (IBD), and it has raised questions about the need for the dermatological assessment of the skin before starting biological therapy. Methods: The aim of this study was to assess the frequency of dermal lesions, including cutaneous malignancies, in IBD patients. This retrospective, single-center study evaluated 805 IBD patients who qualified for biological treatment and were subjected to a dermatological assessment. Results: Dermal lesions (DLs) were found in 15.5% (125) of IBD patients. A risk factor for DLs was higher with body mass index (OR = 1.08, 95% CI [1.02; 1.14], p = 0.007). Surprisingly, there was no effect of thiopurines between the groups with and without DLs (90.4% vs. 84.6%, MD = 0.06, 95% CI [0.01; 0.12], p = 0.118). Moreover, cutaneous malignancies were diagnosed in 9 cases (1.1%), including 4 basal cell carcinomas, 4 squamous cell carcinomas, and 1 melanoma skin cancer. Only 13.4% of patients complied with our strict policy of skin surveillance every 6–8 months. Conclusions: DLs, including cutaneous malignancies, are common in patients with IBD, making skin monitoring at the initiation of biological treatment an extremely useful tool. The lack of effect of the drugs used suggests that skin surveillance is necessary in all IBD patients. The low compliance of skin monitoring among immunosuppressed patients indicates the need for better education on the prevention of cutaneous malignancies.
- Open Access
- 30 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 913
Awareness and Compliance with the Recommendations of Primary and Secondary Prevention of Cancer in Patients with Inflammatory Bowel Disease
Introduction: Patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are at high risk of developing malignancies, so prevention and adherence to cancer screening may improve detection. The aim of this study was to assess compliance with medical recommendations, especially primary and secondary prevention of cancer. Methods: This one-center cross-sectional study was carried out between June and December 2021 amongst patients at the Department of Internal Medicine and Gastroenterology, IBD Division, National Medical Institute of Ministry of Interior Affairs and Administrations, or the outpatient clinic. Patients with IBD were asked to complete an anonymous questionnaire, which included 42 questions concerning lifestyle, cancer risk factors, cancer history, and checkups. Statistical methods: The results of the qualitative variables were expressed as frequencies and percentages. We used Fisher’s exact test and the Chi-squared test. A value of p < 0.05 was considered significant. Statistical analyses were performed with the SPSS statistical package. Results: A total of 313 patients were enrolled in the study: 145 women and 168 men. In the group, 182 had Crohn’s disease (CD), 120 had ulcerative colitis (UC), and 11 with IBDU (unclassified IBD). Most participants had a disease duration of over 8 years and received biological treatment, corticoids, and/or immunosuppressive therapy. Amongst respondents, 17% (31) of patients with CD and 25.8% (31) with UC were overweight, and 10.5% (19) with CD and 15.8% (19) with UC were obese (p = 0.017). We found that 16.3% of all respondents were smokers (79.6% (144) with CD, 90.8% (109) with UC, and 72.7% (8) with IBDU; p = 0.053), and 33.9% declared that they consumed alcohol (39.4% (71) with CD, 26.9% (32) with UC, and 18.2% (2) with IBDU; p = 0.045). A total of 25.4% of patients were exposed to UV radiation, but only 18.8% used sunblock. In addition, 58.8% (67) of patients with CD and 35.8% (19) with UC receiving immunosuppressants had regular laboratory tests (p = 0.02). Furthermore, 41.4% (46) of patients with UC, 27.1% (49) of patients with CD, and 70.0% (7) of patients with IBDU declared not to perform any dermatological control (p = 0.013). A total of 77% of patients had abdominal ultrasound. Out of 52.9% of patients for whom colonoscopy was recommended, only 27.3% had it performed (16.9% (30) with CD vs. 43.1% (50) with UC p < 0.001). Most examinations were ordered by gastroenterologists. Female patients had regular breast control (CD, 78.6% (66); UC, 91.2% (52); IBDU, 50% (2); p = 0.034), and 93.8% (76) had gynecological examinations. Additionally, 80.2% of patients knew about HPV, but most declared not to be vaccinated. A total of 17.9% of patients had urological control, but most had no important pathology detected. Conclusions: According to our study, many patients are still exposed to risk factors, such as obesity, smoking, and low physical activity, that are modifiable. Laboratory tests in patients with immunosuppressive treatment should be performed regularly. Systematic control, especially dermatological checkups, should be recommended. Additionally, not only gastrologists but also other specialists and GPs should remind patients about regular checkups. Primary prevention, such as HPV vaccinations, should be recommended to all patients.
- 30 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 913
Open AccessAwareness and Compliance with the Recommendations of Primary and Secondary Prevention of Cancer in Patients with Inflammatory Bowel Disease
Introduction: Patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are at high risk of developing malignancies, so prevention and adherence to cancer screening may improve detection. The aim of this study was to assess compliance with medical recommendations, especially primary and secondary prevention of cancer. Methods: This one-center cross-sectional study was carried out between June and December 2021 amongst patients at the Department of Internal Medicine and Gastroenterology, IBD Division, National Medical Institute of Ministry of Interior Affairs and Administrations, or the outpatient clinic. Patients with IBD were asked to complete an anonymous questionnaire, which included 42 questions concerning lifestyle, cancer risk factors, cancer history, and checkups. Statistical methods: The results of the qualitative variables were expressed as frequencies and percentages. We used Fisher’s exact test and the Chi-squared test. A value of p < 0.05 was considered significant. Statistical analyses were performed with the SPSS statistical package. Results: A total of 313 patients were enrolled in the study: 145 women and 168 men. In the group, 182 had Crohn’s disease (CD), 120 had ulcerative colitis (UC), and 11 with IBDU (unclassified IBD). Most participants had a disease duration of over 8 years and received biological treatment, corticoids, and/or immunosuppressive therapy. Amongst respondents, 17% (31) of patients with CD and 25.8% (31) with UC were overweight, and 10.5% (19) with CD and 15.8% (19) with UC were obese (p = 0.017). We found that 16.3% of all respondents were smokers (79.6% (144) with CD, 90.8% (109) with UC, and 72.7% (8) with IBDU; p = 0.053), and 33.9% declared that they consumed alcohol (39.4% (71) with CD, 26.9% (32) with UC, and 18.2% (2) with IBDU; p = 0.045). A total of 25.4% of patients were exposed to UV radiation, but only 18.8% used sunblock. In addition, 58.8% (67) of patients with CD and 35.8% (19) with UC receiving immunosuppressants had regular laboratory tests (p = 0.02). Furthermore, 41.4% (46) of patients with UC, 27.1% (49) of patients with CD, and 70.0% (7) of patients with IBDU declared not to perform any dermatological control (p = 0.013). A total of 77% of patients had abdominal ultrasound. Out of 52.9% of patients for whom colonoscopy was recommended, only 27.3% had it performed (16.9% (30) with CD vs. 43.1% (50) with UC p < 0.001). Most examinations were ordered by gastroenterologists. Female patients had regular breast control (CD, 78.6% (66); UC, 91.2% (52); IBDU, 50% (2); p = 0.034), and 93.8% (76) had gynecological examinations. Additionally, 80.2% of patients knew about HPV, but most declared not to be vaccinated. A total of 17.9% of patients had urological control, but most had no important pathology detected. Conclusions: According to our study, many patients are still exposed to risk factors, such as obesity, smoking, and low physical activity, that are modifiable. Laboratory tests in patients with immunosuppressive treatment should be performed regularly. Systematic control, especially dermatological checkups, should be recommended. Additionally, not only gastrologists but also other specialists and GPs should remind patients about regular checkups. Primary prevention, such as HPV vaccinations, should be recommended to all patients.
- Open Access
- 28 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 458
Effect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel Disease—Results of a Prospective Single-Centre Study
Introduction: Anaemia and bone metabolism alterations are common in inflammatory bowel disease (IBD), which is a heterogeneous group of diseases that include Crohn’s disease (CD) and ulcerative colitis (UC) with a rich intestinal and extraintestinal symptomatology. All these make the diagnostic procedures complicated and difficult. Purpose and scope: The aim of this study was to assess the effect of parenteral iron administration on biomarkers of mineral and bone homeostasis over time. Materials and methods: The study was a single-centre non-randomised prospective study. It was carried out between 2016 and 2020 in a group of patients in the Department of Internal Medicine and Gastroenterology Subunit of Inflammatory Bowel Diseases at the National Institute of Medicine of the Ministry of the Interior and Administration in Warsaw. At the first examination, the baseline disease severity, initial evaluation of anaemia (morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid) and bone mineral metabolism including C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), was initially assessed. On the basis of peripheral blood counts, an appropriate dose of iron (iron derisomaltose or caboxymaltose) was administered. During the subsequent appointments on week 1, 4, and 12 morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid, C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), were evaluated. Results: A total of 56 patients were enrolled into the study: 24 women and 32 men. In the group, 32 patients had Crohn’s disease (CD) and 24 had ulcerative colitis (UC). We found a statistically significant increase in the concentration of albumin (p = 0.031), haemoglobin (p < 0.001), haematocrit (p < 0.001), MCV (p < 0.001), MCHC (p = 0.001), iron (p < 0.001) and ferritin (p < 0.001) after the administration of parenteral iron. The influence of individual iron formulations on the analysed parameters (phosphate concentration in serum and in the urine, iFGF23, P1NP, PTH, vitamin D, haemoglobin and ferritin) was similar. Interestingly, an inverse correlation was found between the concentration of phosphorus in the blood and iFGF23 at certain time-points; however, in the study group they did not significantly affect the disturbances of calcium and phosphate metabolism. Conclusions: In the study group, transient and non-significant disorders of phosphate metabolism were found, which does not constitute a contraindication to treatment with parenteral iron in inflammatory bowel disease patients, which was safe and efficient.
- 28 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 458
Open AccessEffect of Intravenous Iron Administration on Bone Mineral and Iron Homeostasis in Patients with Inflammatory Bowel Disease—Results of a Prospective Single-Centre Study
Introduction: Anaemia and bone metabolism alterations are common in inflammatory bowel disease (IBD), which is a heterogeneous group of diseases that include Crohn’s disease (CD) and ulcerative colitis (UC) with a rich intestinal and extraintestinal symptomatology. All these make the diagnostic procedures complicated and difficult. Purpose and scope: The aim of this study was to assess the effect of parenteral iron administration on biomarkers of mineral and bone homeostasis over time. Materials and methods: The study was a single-centre non-randomised prospective study. It was carried out between 2016 and 2020 in a group of patients in the Department of Internal Medicine and Gastroenterology Subunit of Inflammatory Bowel Diseases at the National Institute of Medicine of the Ministry of the Interior and Administration in Warsaw. At the first examination, the baseline disease severity, initial evaluation of anaemia (morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid) and bone mineral metabolism including C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), was initially assessed. On the basis of peripheral blood counts, an appropriate dose of iron (iron derisomaltose or caboxymaltose) was administered. During the subsequent appointments on week 1, 4, and 12 morphology, iron (Fe), total iron binding capacity (TIBC), ferritin, vitamin B12, folic acid, C-reactive protein (CRP), albumins, alkaline phosphatase (ALP), Calcium, osteocalcin, phosphate in serum and in urine, parathyroid hormone (PTH), vitamin D3, fibroblast growth factor (iFGF23) and procollagen type 1N propeptide (P1NP) C-terminal telopeptide (CTX), were evaluated. Results: A total of 56 patients were enrolled into the study: 24 women and 32 men. In the group, 32 patients had Crohn’s disease (CD) and 24 had ulcerative colitis (UC). We found a statistically significant increase in the concentration of albumin (p = 0.031), haemoglobin (p < 0.001), haematocrit (p < 0.001), MCV (p < 0.001), MCHC (p = 0.001), iron (p < 0.001) and ferritin (p < 0.001) after the administration of parenteral iron. The influence of individual iron formulations on the analysed parameters (phosphate concentration in serum and in the urine, iFGF23, P1NP, PTH, vitamin D, haemoglobin and ferritin) was similar. Interestingly, an inverse correlation was found between the concentration of phosphorus in the blood and iFGF23 at certain time-points; however, in the study group they did not significantly affect the disturbances of calcium and phosphate metabolism. Conclusions: In the study group, transient and non-significant disorders of phosphate metabolism were found, which does not constitute a contraindication to treatment with parenteral iron in inflammatory bowel disease patients, which was safe and efficient.
- Open Access
Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
Introduction: There are many known risk factors for osteoporosis (OST) among patients with inflammatory bowel disease (IBD), one of which is physical activity. Material and methods: The aim of the study is to assess the frequency and risk factors of OST among 232 patients with IBD compared to a group of 199 patients without IBD. The participants underwent dual-energy X-ray absorptiometry, laboratory tests, and completed a questionnaire about their physical activity. Results: It was found that 7.3% of IBD patients suffered from OST. Male gender, ulcerative colitis, extensive inflammation in the intestine, exacerbation of disease, rare physical activity, other forms of physical activity, past fractures, lower levels of osteocalcin, and higher levels of C-terminal telopeptide of type 1 collagen were risk factors for OST. As many as 70.6% of OST patients were rarely physically active. Conclusions: OST is a common problem in IBD patients. OST risk factors differ significantly between the general population and those with IBD. Modifiable factors can be influenced by patients and by physicians. The key to OST prophylaxis may be regular physical activity, which should be recommended in clinical remission. It may also prove valuable to use markers of bone turnover in diagnostics, which may enable decisions regarding therapy.
Open AccessRisk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease—Do We Already Know Everything?
Introduction: There are many known risk factors for osteoporosis (OST) among patients with inflammatory bowel disease (IBD), one of which is physical activity. Material and methods: The aim of the study is to assess the frequency and risk factors of OST among 232 patients with IBD compared to a group of 199 patients without IBD. The participants underwent dual-energy X-ray absorptiometry, laboratory tests, and completed a questionnaire about their physical activity. Results: It was found that 7.3% of IBD patients suffered from OST. Male gender, ulcerative colitis, extensive inflammation in the intestine, exacerbation of disease, rare physical activity, other forms of physical activity, past fractures, lower levels of osteocalcin, and higher levels of C-terminal telopeptide of type 1 collagen were risk factors for OST. As many as 70.6% of OST patients were rarely physically active. Conclusions: OST is a common problem in IBD patients. OST risk factors differ significantly between the general population and those with IBD. Modifiable factors can be influenced by patients and by physicians. The key to OST prophylaxis may be regular physical activity, which should be recommended in clinical remission. It may also prove valuable to use markers of bone turnover in diagnostics, which may enable decisions regarding therapy.
- Open Access
- 16 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4138
Bone Metabolism Alteration in Patients with Inflammatory Bowel Disease
Background: Metabolic bone disease is a common disorder, but there is a lack of data on it in patients with inflammatory bowel disease (IBD). Methods: In this prospective, one-centre study, we assessed bone mineral and vitamin D alterations in 187 IBD patients (119 with Crohn’s disease (CD) and 68 with ulcerative colitis (UC)). Results: While 81.3% of the patients had vitamin D deficiency, 14.2% of them had a severe deficiency. Elevated serum PTH concentrations were found in 14.9% of the patients. Only in 4.1% of cases was there an elevated level of a serum marker for bone formation (osteocalcin), whereas in 14.4% of cases, the bone resorption marker (CTX) was raised. The concentration of phosphate in urine was higher in the CD than in the UC group (51.20 vs. 31.25; p = 0.003). PTH was negatively associated with vitamin D level. Among the patients receiving corticosteroids, the CTX and CRP median levels were higher (0.49 vs. 0.38; p = 0.013 and 6.45 vs. 2.2; p = 0.029, respectively) compared with the group who did not receive them. Urine phosphate levels were lower (48.60 vs. 26.00; p = 0.005), as were osteocalcin (15.50 vs. 23.80; p < 0.001), and PTH (29.05 vs. 36.05; p = 0.018). Conclusions: Bone mineral alterations were common in patients with IBD, mostly in the CD patients. This may be associated with poor absorption, making CD patients vulnerable to changes in bone mineralization. Vitamin D supplementation remains crucial, especially when taking corticosteroids.
- 16 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4138
Open AccessBone Metabolism Alteration in Patients with Inflammatory Bowel Disease
Background: Metabolic bone disease is a common disorder, but there is a lack of data on it in patients with inflammatory bowel disease (IBD). Methods: In this prospective, one-centre study, we assessed bone mineral and vitamin D alterations in 187 IBD patients (119 with Crohn’s disease (CD) and 68 with ulcerative colitis (UC)). Results: While 81.3% of the patients had vitamin D deficiency, 14.2% of them had a severe deficiency. Elevated serum PTH concentrations were found in 14.9% of the patients. Only in 4.1% of cases was there an elevated level of a serum marker for bone formation (osteocalcin), whereas in 14.4% of cases, the bone resorption marker (CTX) was raised. The concentration of phosphate in urine was higher in the CD than in the UC group (51.20 vs. 31.25; p = 0.003). PTH was negatively associated with vitamin D level. Among the patients receiving corticosteroids, the CTX and CRP median levels were higher (0.49 vs. 0.38; p = 0.013 and 6.45 vs. 2.2; p = 0.029, respectively) compared with the group who did not receive them. Urine phosphate levels were lower (48.60 vs. 26.00; p = 0.005), as were osteocalcin (15.50 vs. 23.80; p < 0.001), and PTH (29.05 vs. 36.05; p = 0.018). Conclusions: Bone mineral alterations were common in patients with IBD, mostly in the CD patients. This may be associated with poor absorption, making CD patients vulnerable to changes in bone mineralization. Vitamin D supplementation remains crucial, especially when taking corticosteroids.